Kaken Pharmaceutical Co., Ltd.

TSE:4521 Stock Report

Market Cap: JP¥154.3b

Kaken Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Kaken Pharmaceutical's earnings have been declining at an average annual rate of -12.2%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 3.2% per year.

Key information

-12.22%

Earnings growth rate

-11.89%

EPS growth rate

Pharmaceuticals Industry Growth3.41%
Revenue growth rate3.16%
Return on equity-2.63%
Net Margin-5.06%
Next Earnings Update13 May 2026

Recent past performance updates

We Think You Can Look Beyond Kaken Pharmaceutical's (TSE:4521) Lackluster Earnings

Nov 18
We Think You Can Look Beyond Kaken Pharmaceutical's (TSE:4521) Lackluster Earnings

Recent updates

Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥95.00

Dec 19
Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥95.00

Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥95.00

Nov 29
Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥95.00

We Think You Can Look Beyond Kaken Pharmaceutical's (TSE:4521) Lackluster Earnings

Nov 18
We Think You Can Look Beyond Kaken Pharmaceutical's (TSE:4521) Lackluster Earnings

We Think Kaken Pharmaceutical's (TSE:4521) Robust Earnings Are Conservative

May 19
We Think Kaken Pharmaceutical's (TSE:4521) Robust Earnings Are Conservative

We Think Kaken Pharmaceutical (TSE:4521) Can Manage Its Debt With Ease

May 12
We Think Kaken Pharmaceutical (TSE:4521) Can Manage Its Debt With Ease

There's Reason For Concern Over Kaken Pharmaceutical Co., Ltd.'s (TSE:4521) Price

Apr 15
There's Reason For Concern Over Kaken Pharmaceutical Co., Ltd.'s (TSE:4521) Price

Kaken Pharmaceutical (TSE:4521) Is Due To Pay A Dividend Of ¥75.00

Mar 27
Kaken Pharmaceutical (TSE:4521) Is Due To Pay A Dividend Of ¥75.00

Kaken Pharmaceutical (TSE:4521) Will Pay A Dividend Of ¥75.00

Mar 13
Kaken Pharmaceutical (TSE:4521) Will Pay A Dividend Of ¥75.00

Kaken Pharmaceutical (TSE:4521) Has Affirmed Its Dividend Of ¥75.00

Feb 27
Kaken Pharmaceutical (TSE:4521) Has Affirmed Its Dividend Of ¥75.00

Kaken Pharmaceutical (TSE:4521) Is Due To Pay A Dividend Of ¥75.00

Feb 10
Kaken Pharmaceutical (TSE:4521) Is Due To Pay A Dividend Of ¥75.00

Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Jan 10
Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00

Dec 20
Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00

Kaken Pharmaceutical (TSE:4521) Will Pay A Dividend Of ¥75.00

Dec 02
Kaken Pharmaceutical (TSE:4521) Will Pay A Dividend Of ¥75.00

Estimating The Intrinsic Value Of Kaken Pharmaceutical Co., Ltd. (TSE:4521)

Aug 13
Estimating The Intrinsic Value Of Kaken Pharmaceutical Co., Ltd. (TSE:4521)

Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Jul 26
Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00

Jul 11
Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00

Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Mar 04
Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Revenue & Expenses Breakdown

How Kaken Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:4521 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2575,662-3,83219,91923,813
30 Sep 2582,01965119,65624,424
30 Jun 2594,64812,46218,67321,109
31 Mar 2594,03513,94518,50118,725
31 Dec 2493,34920,52516,89214,598
30 Sep 2487,24518,24316,24612,778
30 Jun 2472,1487,26916,30612,941
31 Mar 2472,0448,02516,16512,543
31 Dec 2372,0962,96616,10217,981
30 Sep 2372,3363,54416,09717,197
30 Jun 2372,9375,04315,68516,359
31 Mar 2372,9845,44015,47615,789
31 Dec 2273,8998,45215,5978,695
30 Sep 2275,2658,79215,7268,742
30 Jun 2275,7789,09415,7978,585
31 Mar 2276,0349,54915,8338,420
31 Dec 2175,60512,71716,2587,909
30 Sep 2175,77812,90016,2707,477
30 Jun 2175,36212,94716,3617,028
31 Mar 2174,97913,40516,1556,736
31 Dec 2076,13614,75016,1596,539
30 Sep 2080,85117,04916,3476,351
30 Jun 2084,96718,36416,5906,382
31 Mar 2089,23219,37017,3206,418
31 Dec 1991,75919,08217,7157,258
30 Sep 1991,81418,48218,0587,887
30 Jun 1992,36518,56618,4978,291
31 Mar 1994,16517,77518,72410,261
31 Dec 1894,12316,43119,41310,118
30 Sep 1896,09117,01519,67210,216
30 Jun 1897,59817,61519,9529,895
31 Mar 1898,43019,04320,1748,152
31 Dec 1799,40520,89319,8277,243
30 Sep 1799,16021,43919,8546,467
30 Jun 17100,21821,68419,9436,387
31 Mar 17101,47922,01720,0206,450
31 Dec 16103,26418,99220,2906,476
30 Sep 16106,93620,10620,3026,545
30 Jun 16108,32520,63920,1916,374
31 Mar 16109,73021,14320,3025,883
31 Dec 15108,16522,65120,0777,201
30 Sep 15104,63018,96620,2207,206
30 Jun 15100,05815,79220,6067,403

Quality Earnings: 4521 is currently unprofitable.

Growing Profit Margin: 4521 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4521 is unprofitable, and losses have increased over the past 5 years at a rate of 12.2% per year.

Accelerating Growth: Unable to compare 4521's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4521 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.3%).

Return on Equity

High ROE: 4521 has a negative Return on Equity (-2.63%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/01 21:10
End of Day Share Price 2026/05/01 00:00
Earnings2025/12/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kaken Pharmaceutical Co., Ltd. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kazuaki HashiguchiDaiwa Securities Co. Ltd.
Junya YamazakiJefferies LLC
Toshiyuki IwataMizuho Securities Co., Ltd.